Neumora Therapeutics(NMRA) - 2023 Q4 - Annual Results

Exhibit 99.1 Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update On-track to report topline Phase 3 data from the KOASTAL-1 study with navacaprant in MDD in the second half of 2024 and Phase 1 data with NMRA-266 in healthy adult participants mid-2024 Strong financial position with $463.8 million in cash, cash equivalents and marketable securities expected to support operations into 2026 WATERTOWN, Mass., March 7, 2024 – Neumora Therapeutics, Inc. (Na ...